CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors

References

• GoldsteinJAClinical relevance of genetic polymorphisms in the human CYP2C subfamilyBr J Clin Pharmacol200152434935511678778
   PubMed Web of Science ®Google Scholar
• DestaZZhaoXShinJGFlockhartDAClinical significance of the cytochrome P450 2C19 genetic polymorphismClin Pharmacokinet2002411291395812222994
   PubMed Web of Science ®Google Scholar
• IbeanuGCBlaisdellJFergusonRJA novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoinJ Pharmacol Exp Ther1999290263564010411572
   PubMed Web of Science ®Google Scholar
• MiaoJLiuRLiZCytochrome P-450 polymorphisms and response to clopidogrelN Engl J Med2009360212250225119469033
   PubMed Web of Science ®Google Scholar
• HulotJSBuraAVillardECytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjectsBlood200610872244224716772608
   PubMed Web of Science ®Google Scholar
• TrenkDHochholzerWFrommMFCytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stentsJ Am Coll Cardiol200851201925193418482659
   PubMed Web of Science ®Google Scholar
• SibbingDStegherrJLatzWCytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary interventionEur Heart J200930891692219193675
   PubMed Web of Science ®Google Scholar
• ColletJPHulotJSPenaACytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyLancet2009373966030931719108880
   PubMed Web of Science ®Google Scholar
• GeislerTSchaeffelerEDipponJCYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantationPharmacogenomics2008991251125918781853
   PubMed Web of Science ®Google Scholar
• SimonTVerstuyftCMary-KrauseMAcute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) InvestigatorsGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med2009360436337519106083
   PubMed Web of Science ®Google Scholar
• PirmohamedMParkBKGenetic susceptibility to adverse drug reactionsTrends Pharmacol Sci200122629830511395158
   PubMed Web of Science ®Google Scholar
• SameerAEAmanyGMAbdelaAAFadelSACYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza StripCan J Clin Pharmacol2009161e156e16219193970
   PubMedGoogle Scholar
• FreedmanJEHylekEMClopidogrel, genetics, and drug responsivenessN Engl J Med2009360441141319164193
   PubMed Web of Science ®Google Scholar
• TassaneeyakulWMahatthanatrakulWNiwatananunKCYP2C19 genetic polymorphism in Thai, Burmese and Karen populationsDrug Metab Pharmacokinet200621428629016946555
   PubMed Web of Science ®Google Scholar
• KoselerAIlcolYOUlusIHFrequency of mutated allele CYP2D6*4 in the Turkish populationPharmacology200779420320617374963
   PubMed Web of Science ®Google Scholar
• SmallDSFaridNAPayneCDEffects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelJ Clin Pharmacol200848447548418303127
   PubMed Web of Science ®Google Scholar
• BrandtJTCloseSLIturriaSJCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost20075122429243617900275
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEPlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantationBlood Coagul Fibrinolysis2004151899315166949
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEContribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrelArterioscler Thromb Vasc Biol20062681895190016645157
   PubMed Web of Science ®Google Scholar
• FontanaPDupontAGandrilleSAdenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjectsCirculation2003108898999512912815
   PubMed Web of Science ®Google Scholar
• GiustiBGoriAMMarcucciRCytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patientsPharmacogenet Genomics200717121057106418004210
   PubMed Web of Science ®Google Scholar
• TaubertDvon BeckerathNGrimbergGImpact of P-glycoprotein on clopidogrel absorptionClin Pharmacol Ther200680548650117112805
   PubMed Web of Science ®Google Scholar
• GoldsteinJAIshizakiTChibaKFrequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populationsPharmacogenetics19977159649110363
   PubMedGoogle Scholar
• HerrlinKMasseleAYJandeMBantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotypeClin Pharmacol Ther19986443914019797796
   PubMed Web of Science ®Google Scholar
• AllabiACGalaJLDesagerJPHeusterspreuteMHorsmansYGenetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populationsBr J Clin Pharmacol200356665365714616425
   PubMed Web of Science ®Google Scholar
• KubotaTChibaKIshizakiTGenotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese populationClin Pharmacol Ther19966066616668988068
   PubMed Web of Science ®Google Scholar
• MüllerIBestaFSchulzCMassbergSSchönigAGawazMPrevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placementThromb Haemost200389578378712719773
   PubMed Web of Science ®Google Scholar
• HeNYanFXHuangSLCYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai populationEur J Clin Pharmacol2002581151811956668
   PubMed Web of Science ®Google Scholar
• XiaoZSGoldsteinJAXieHGDifferences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant alleleJ Pharmacol Exp Ther199728116046099103550
   PubMed Web of Science ®Google Scholar
• PangYSWongLPLeeTCMustafaAMMohamedZLangCCGenetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjectsBr J Clin Pharmacol200458333233515327595
   PubMed Web of Science ®Google Scholar
• LambaJKDhimanRKKohliKKGenetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjectsClin Pharmacol Ther19986344224279585796
   PubMed Web of Science ®Google Scholar
• AynaciogluASSachseCBozkurtALow frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish populationClin Pharmacol Ther199966218519210460072
   PubMed Web of Science ®Google Scholar
• OzawaSSoyamaASaekiMEthnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1Drug Metab Pharmacokinet2004192839515499174
   PubMedGoogle Scholar
• ZandNTajikNMoghaddamASMilanianIGenetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian populationClin Exp Pharmacol Physiol2007341–210210517201743
   PubMed Web of Science ®Google Scholar
• de MoraisSMWilkinsonGRBlaisdellJNakamuraKMeyerUAGoldsteinJAThe major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humansJ Biol Chem19942692215419154228195181
   PubMed Web of Science ®Google Scholar
• NakamuraKGotoFRayWAInterethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populationsClin Pharmacol Ther19853844024084042523
   PubMed Web of Science ®Google Scholar
• ScottSASangkuhlKGardnerEEClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-452C19 (CYP2C19) genotype and clopidogrel therapyClin Pharmacol Ther201190232833221716271
   PubMed Web of Science ®Google Scholar
• SimSCRisingerCDahlMLA common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClin Pharmacol Ther200679110311316413245
   PubMed Web of Science ®Google Scholar